{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:39:40Z","timestamp":1777531180324,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T00:00:00Z","timestamp":1554163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Novartis Oncology","award":["EUTOS 2016"],"award-info":[{"award-number":["EUTOS 2016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00432-019-02910-6","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T06:40:23Z","timestamp":1554187223000},"page":"1645-1650","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)"],"prefix":"10.1007","volume":"145","author":[{"given":"Susanne","family":"M\u00f6bius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Himsel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Maier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajnalka","family":"Andrikovics","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Meggyesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Machova-Polakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Zizkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Jurcek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Semir","family":"Mesanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Zadro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Gottardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Haenig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schuld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas C. P.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-489X","authenticated-orcid":false,"given":"Thomas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,2]]},"reference":[{"key":"2910_CR2","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 122:872\u2013884. \n                    https:\/\/doi.org\/10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"issue":"Suppl 2","key":"2910_CR3","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","volume":"94","author":"M Baccarani","year":"2015","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G (2015) A review of the European LeukemiaNet recommendations for the management of CML. Ann Hematol 94(Suppl 2):S141\u2013S147. \n                    https:\/\/doi.org\/10.1007\/s00277-015-2322-2","journal-title":"Ann Hematol"},{"key":"2910_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","volume":"20","author":"S Branford","year":"2006","unstructured":"Branford S et al (2006) Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 20:1925\u20131930. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2404388","journal-title":"Leukemia"},{"key":"2910_CR5","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S et al (2008) Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112:3330\u20133338. \n                    https:\/\/doi.org\/10.1182\/blood-2008-04-150680","journal-title":"Blood"},{"key":"2910_CR6","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NC Cross","year":"2012","unstructured":"Cross NC, White HE, Muller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26:2172\u20132175. \n                    https:\/\/doi.org\/10.1038\/leu.2012.104","journal-title":"Leukemia"},{"issue":"Suppl 2","key":"2910_CR7","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.1007\/s00277-015-2315-1","volume":"94","author":"NC Cross","year":"2015","unstructured":"Cross NC, Hochhaus A, Muller MC (2015a) Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization. Ann Hematol 94(Suppl 2):S219\u2013S225. \n                    https:\/\/doi.org\/10.1007\/s00277-015-2315-1","journal-title":"Ann Hematol"},{"key":"2910_CR8","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/leu.2015.29","volume":"29","author":"NC Cross","year":"2015","unstructured":"Cross NC et al (2015b) Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 29:999\u20131003. \n                    https:\/\/doi.org\/10.1038\/leu.2015.29","journal-title":"Leukemia"},{"key":"2910_CR9","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1038\/leu.2016.90","volume":"30","author":"NC Cross","year":"2016","unstructured":"Cross NC et al (2016) Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. Leukemia 30:1844\u20131852. \n                    https:\/\/doi.org\/10.1038\/leu.2016.90","journal-title":"Leukemia"},{"key":"2910_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bjh.15542","volume":"182","author":"NCP Cross","year":"2018","unstructured":"Cross NCP et al (2018) Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK. Br J Haematol 182:777\u2013788. \n                    https:\/\/doi.org\/10.1111\/bjh.15542","journal-title":"Br J Haematol"},{"key":"2910_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","volume":"153","author":"L Foroni","year":"2011","unstructured":"Foroni L et al (2011) Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol 153:179\u2013190. \n                    https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08603.x","journal-title":"Br J Haematol"},{"key":"2910_CR12","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J et al (2003) Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program. Leukemia 17:2318\u20132357. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2403135","journal-title":"Leukemia"},{"key":"2910_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103:553\u2013561. \n                    https:\/\/doi.org\/10.1093\/jnci\/djr060","journal-title":"J Natl Cancer Inst"},{"key":"2910_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32:415\u2013423. \n                    https:\/\/doi.org\/10.1200\/jco.2013.49.9020","journal-title":"J Clin Oncol"},{"key":"2910_CR15","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A et al (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054\u20131061. \n                    https:\/\/doi.org\/10.1038\/leu.2009.38","journal-title":"Leukemia"},{"key":"2910_CR16","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A et al (2017) Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376:917\u2013927. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1609324","journal-title":"N Engl J Med"},{"key":"2910_CR17","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118:3123\u20133127. \n                    https:\/\/doi.org\/10.1002\/cncr.26679","journal-title":"Cancer"},{"key":"2910_CR18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP et al (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New Engl J Med 349:1423\u20131432. \n                    https:\/\/doi.org\/10.1056\/NEJMoa030513","journal-title":"New Engl J Med"},{"key":"2910_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T et al (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28\u201337. \n                    https:\/\/doi.org\/10.1182\/blood-2006-01-0092","journal-title":"Blood"},{"key":"2910_CR1","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","volume":"123","author":"E Jabbour","year":"2014","unstructured":"Jabbour E et al (2014) Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494\u2013500. \n                    https:\/\/doi.org\/10.1182\/blood-2013-06-511592","journal-title":"Blood"},{"key":"2910_CR20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L et al (2015) Safety and efficacy of imatinib in CML over a period of 10\u00a0years: data from the randomized CML-study IV. Leukemia 29:1123\u20131132. \n                    https:\/\/doi.org\/10.1038\/leu.2015.36","journal-title":"Leukemia"},{"key":"2910_CR21","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H et al (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 362:2260\u20132270. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1002315","journal-title":"New Engl J Med"},{"key":"2910_CR22","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12:841\u2013851. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(11)70201-7","journal-title":"Lancet Oncol"},{"key":"2910_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159\u2013174","journal-title":"Biometrics"},{"key":"2910_CR24","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.beha.2016.10.014","volume":"29","author":"FX Mahon","year":"2016","unstructured":"Mahon FX (2016) Discontinuation of TKI therapy and \u2018functional\u2019 cure for CML best practice research. Clin Haematol 29:308\u2013313. \n                    https:\/\/doi.org\/10.1016\/j.beha.2016.10.014","journal-title":"Clin Haematol"},{"key":"2910_CR25","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(10)70233-3","journal-title":"Lancet Oncol"},{"key":"2910_CR26","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/leu.2009.168","volume":"23","author":"MC Muller","year":"2009","unstructured":"Muller MC et al (2009) Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23:1957\u20131963. \n                    https:\/\/doi.org\/10.1038\/leu.2009.168","journal-title":"Leukemia"},{"key":"2910_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515\u2013522. \n                    https:\/\/doi.org\/10.1182\/blood-2013-02-483750","journal-title":"Blood"},{"key":"2910_CR28","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0912614","journal-title":"N Engl J Med"},{"key":"2910_CR29","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2016.115","volume":"30","author":"S Saussele","year":"2016","unstructured":"Saussele S, Richter J, Hochhaus A, Mahon FX (2016) The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 30:1638\u20131647. \n                    https:\/\/doi.org\/10.1038\/leu.2016.115","journal-title":"Leukemia"},{"key":"2910_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747\u2013757. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(18)30192-x","journal-title":"Lancet Oncol"},{"key":"2910_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/leu.2014.217","volume":"29","author":"H White","year":"2015","unstructured":"White H et al (2015) A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR. Leukemia 29:369\u2013376. \n                    https:\/\/doi.org\/10.1038\/leu.2014.217","journal-title":"Leukemia"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02910-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-019-02910-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-019-02910-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T23:21:06Z","timestamp":1585696866000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-019-02910-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,2]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2910"],"URL":"https:\/\/doi.org\/10.1007\/s00432-019-02910-6","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,2]]},"assertion":[{"value":"8 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study has been approved by the ethics committee of the Jena University Hospital, Jena, Germany (No. 3944-12\/12).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}